keyword
MENU ▼
Read by QxMD icon Read
search

atherothrombosis

keyword
https://www.readbyqxmd.com/read/28807460/metabolic-syndrome-cluster-does-not-provide-incremental-prognostic-information-in-patients-with-stable-cardiovascular-disease-a-post-hoc-analysis-of-the-aim-high-trial
#1
Radmila Lyubarova, Jennifer G Robinson, Michael Miller, Debra L Simmons, Ping Xu, Beth L Abramson, Marshall B Elam, Todd M Brown, Ruth McBride, Jerome L Fleg, Patrice Desvigne-Nickens, Woubeshet Ayenew, William E Boden
BACKGROUND: Metabolic syndrome (MS) is a well-known risk factor for the development of cardiovascular (CV) disease; yet, controversy persists whether it adds incremental prognostic value in patients with established CV disease. OBJECTIVES: This study was performed to determine if MS is associated with worse CV outcomes in patients with established CV disease treated intensively with statins. METHODS: We performed a post hoc analysis of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial, in which patients with established CV disease and atherogenic dyslipidemia (n = 3414) were randomly assigned to receive extended release niacin or placebo during a mean 36-month follow-up, to assess whether the presence of MS or the number of MS components contributed to CV outcomes...
July 5, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28797175/role-of-lipids-and-intraplaque-hypoxia-in-the-formation-of-neovascularization-in-atherosclerosis
#2
Dimitry A Chistiakov, Alexandra A Melnichenko, Veronika A Myasoedova, Andrey V Grechko, Alexander N Orekhov
According to the current paradigm, chronic vascular inflammation plays a central role in the pathogenesis of atherosclerosis. The plaque progression is typically completed with rupture and subsequent acute cardiovascular complications. Previously, the role of adventitial vasa vasorum in atherogenesis was underestimated. However, investigators then revealed that vasa vasorum neovascularization can be observed when no clinical manifestation of atherosclerosis is present. Vasa vasorum is involved in various proatherogenic processes such as intimal accumulation of inflammatory leukocytes, intimal thickening, necrotic core formation, intraplaque hemorrhage, lesion repture, and atherothrombosis...
August 11, 2017: Annals of Medicine
https://www.readbyqxmd.com/read/28751543/adpase-cd39-fused-to-glycoprotein-vi-fc-boosts-local-antithrombotic-effects-at-vascular-lesions
#3
Heidrun Degen, Oliver Borst, Melanie Ziegler, Ann-Katrin Mojica Munoz, Janina Jamasbi, Britta Walker, Silvia Göbel, Julia Fassbender, Kristin Adler, Richard Brandl, Götz Münch, Reinhard Lorenz, Wolfgang Siess, Meinrad Gawaz, Martin Ungerer
BACKGROUND: GPVI (Glycoprotein VI) is the essential platelet collagen receptor in atherothrombosis. Dimeric GPVI-Fc (Revacept) binds to GPVI binding sites on plaque collagen. As expected, it did not increase bleeding in clinical studies. GPVI-Fc is a potent inhibitor of atherosclerotic plaque-induced platelet aggregation at high shear flow, but its inhibition at low shear flow is limited. We sought to increase the platelet inhibitory potential by fusing GPVI-Fc to the ectonucleotidase CD39 (fusion protein GPVI-CD39), which inhibits local ADP accumulation at vascular plaques, and thus to create a lesion-directed dual antiplatelet therapy that is expected to lack systemic bleeding risks...
July 27, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28747613/increased-carotid-artery-lesion-inflammation-upon-treatment-with-the-cd137-agonistic-antibody-2a
#4
Leif Å Söderström, Hong Jin, April S Caravaca, Maria L Klement, Yuhuang Li, Anton Gisterå, Ulf Hedin, Lars Maegdefessel, Göran K Hansson, Peder S Olofsson
BACKGROUND: Increased inflammatory activity destabilizes the atherosclerotic lesion and may lead to atherothrombosis and symptomatic cardiovascular disease. Co-stimulatory molecules, such as CD137, are key regulators of inflammation, and CD137 activity regulates inflammation in experimental atherosclerosis. Here, we hypothesized that CD137 activation promotes carotid artery inflammation and atherothrombosis.Methods and Results:In a model of inducible atherothrombosis with surgical ligation of the right carotid artery and a subsequent placement of a polyethene cuff, elevated levels of CD137 and CD137 ligand mRNA in atherothrombotic vs...
July 26, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28721158/potential-novel-biomarkers-of-cardiovascular-dysfunction-and-disease-cardiotrophin-1-adipokines-and-galectin-3
#5
Simona Hogas, Stefana C Bilha, Dumitru Branisteanu, Mihai Hogas, Abduzhappar Gaipov, Mehmet Kanbay, Adrian Covic
Cardiovascular disease is one of the main burdens of healthcare systems worldwide. Nevertheless, assessing cardiovascular risk in both apparently healthy individuals and low/high-risk patients remains a difficult issue. Already established biomarkers (e.g. brain natriuretic peptide, troponin) have significantly improved the assessment of major cardiovascular events and diseases but cannot be applied to all patients and in some cases do not provide sufficiently accurate information. In this context, new potential biomarkers that reflect various underlying pathophysiological cardiac and vascular modifications are needed...
June 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28709878/differential-tbxa2-receptor-transcript-stability-is-dependent-on-the-c924t-polymorphism
#6
Vincenzo De Iuliis, Sebastiano Ursi, Alfonso Pennelli, Marika Caruso, Angela Nunziata, Antonio Marino, Vincenzo Flati, Francesco Cipollone, Maria Adele Giamberardino, Gianfranco Vitullo, Elena Toniato, Pio Conti, Stefano Martinotti
BACKGROUND: In order to better characterize the molecular mechanisms involved in processing mutated transcripts, we investigated the post-transcriptional role of the C924T polymorphism (rs4523) located in the 3' region of the TBXA2R gene. METHODS: and RESULTS: Experiments of dose response with Actinomycin D on MEG-01 human cell line showed a significant decrease on cell viability that was more evident on cells treated for 24h. In addition, we showed that treatments with 5-10μM, 15μM and 20μM of actinomycin D reduced cell viability by 44%, 72% and 75%, respectively, compared to the control group...
July 11, 2017: Prostaglandins & Other Lipid Mediators
https://www.readbyqxmd.com/read/28697231/gadolinium-terbium-hybrid-macromolecular-complexes-for-bimodal-imaging-of-atherothrombosis
#7
Nguy N Tr Ng Nghia, Eric Tinet, Dominique Ettori, Anne Beilvert, Graciela Pavon-Djavid, Murielle Maire, Phalla Ou, Jean-Michel Tualle, Frédéric Chaubet
No abstract text is available yet for this article.
July 1, 2017: Journal of Biomedical Optics
https://www.readbyqxmd.com/read/28692742/vitamin-k-antagonists-with-or-without-long-term-antiplatelet-therapy-in-outpatients-with-stable-coronary-artery-disease-and-atrial-fibrillation-association-with-ischemic-and-bleeding-events
#8
Gilles Lemesle, Gregory Ducrocq, Yedid Elbez, Eric Van Belle, Shinya Goto, Christopher P Cannon, Christophe Bauters, Deepak L Bhatt, Philippe Gabriel Steg
BACKGROUND: It remains uncertain whether patients with atrial fibrillation (AF) requiring long-term oral anticoagulation (OAC) and with stable coronary artery disease (CAD) should receive antiplatelet therapy (APT) in addition to OAC. HYPOTHESIS: APT in addition to OAC would be more effective than OAC alone in preventing ischaemic events in such patients. METHODS: In the international REduction of Atherothrombosis for Continued Health (REACH) Registry including 68 236 outpatients with or at risk for atherothrombosis, we identified 2347 patients with stable CAD and AF receiving vitamin K antagonists (VKA)...
July 10, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28676852/cd40l-and-its-receptors-in-atherothrombosis-an-update
#9
REVIEW
Nathaly Anto Michel, Andreas Zirlik, Dennis Wolf
CD40L (CD154), a member of the tumor necrosis factor superfamily, is a co-stimulatory molecule that was first discovered on activated T cells. Beyond its fundamental role in adaptive immunity-ligation of CD40L to its receptor CD40 is a prerequisite for B cell activation and antibody production-evidence from more than two decades has expanded our understanding of CD40L as a powerful modulator of inflammatory pathways. Although inhibition of CD40L with neutralizing antibodies has induced life-threatening side effects in clinical trials, the discovery of cell-specific effects and novel receptors with distinct functional consequences has opened a new path for therapies that specifically target detrimental properties of CD40L...
2017: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28641133/abc-transporters-in-megakaryopoiesis-and-platelet-activity
#10
REVIEW
Wei Wang, Lorena Buitrago, Ying Wang
ATP-binding cassette (ABC) is a family of transporters that facilitates the translocation of substrates across cell membrane using its ATPase subunit. These transporters have key roles in multidrug resistance, lipid homeostasis, antigen processing, immunity, cell proliferation and hematopoiesis. Some ABC transporters are selectively expressed on megakaryocyte progenitor, megakaryocyte and its cellular fragment platelet. However, the role of ABC transporters in hemostasis and thrombosis were not well explored until recently...
June 14, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28630267/a-structured-review-of-antithrombotic-therapy-in-peripheral-artery-disease-with-a-focus-on-revascularization-a-tasc-intersociety-consensus-for-the-management-of-peripheral-artery-disease-initiative
#11
REVIEW
Connie N Hess, Lars Norgren, Gary M Ansel, Warren H Capell, John P Fletcher, F Gerry R Fowkes, Anders Gottsäter, Kerry Hitos, Michael R Jaff, Joakim Nordanstig, William R Hiatt
Peripheral artery disease affects >200 million people worldwide and is associated with significant limb and cardiovascular morbidity and mortality. Limb revascularization is recommended to improve function and quality of life for symptomatic patients with peripheral artery disease with intermittent claudication who have not responded to medical treatment. For patients with critical limb ischemia, the goals of revascularization are to relieve pain, help wound healing, and prevent limb loss. The baseline risk of cardiovascular and limb-related events demonstrated among patients with stable peripheral artery disease is elevated after revascularization and related to atherothrombosis and restenosis...
June 20, 2017: Circulation
https://www.readbyqxmd.com/read/28628560/genetic-coding-variants-in-the-niacin-receptor-hydroxyl-carboxylic-acid-receptor-2-and-response-to-niacin-therapy
#12
Sony Tuteja, Lu Wang, Richard L Dunbar, Jinbo Chen, Stephanie DerOhannessian, Santica M Marcovina, Marshall Elam, Ellis Lader, Daniel J Rader
OBJECTIVE: Niacin has been used for seven decades to modulate plasma lipids, but its mechanism of action is still unclear. We sought to determine whether variants in the niacin receptor gene, hydroxyl-carboxylic receptor 2 (HCAR2), are associated with lipid response to treatment. PARTICIPANTS AND METHODS: Coding variants, rs7314976 (p.R311C) and rs2454727 (p.M317I), were genotyped in 2067 participants from the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial...
August 2017: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/28627575/label-free-detection-of-aggregated-platelets-in-blood-by-machine-learning-aided-optofluidic-time-stretch-microscopy
#13
Yiyue Jiang, Cheng Lei, Atsushi Yasumoto, Hirofumi Kobayashi, Yuri Aisaka, Takuro Ito, Baoshan Guo, Nao Nitta, Natsumaro Kutsuna, Yasuyuki Ozeki, Atsuhiro Nakagawa, Yutaka Yatomi, Keisuke Goda
According to WHO, about 10 million new cases of thrombotic disorders are diagnosed worldwide every year. Thrombotic disorders, including atherothrombosis (the leading cause of death in the US and Europe), are induced by occlusion of blood vessels, due to the formation of blood clots in which aggregated platelets play an important role. The presence of aggregated platelets in blood may be related to atherothrombosis (especially acute myocardial infarction) and is, hence, useful as a potential biomarker for the disease...
June 19, 2017: Lab on a Chip
https://www.readbyqxmd.com/read/28602550/examining-the-applicability-of-sprint-in-patients-with-subclinical-or-established-atherothrombotic-disease-a-reach-registry-analysis
#14
Anubodh Varshney, Ph Gabriel Steg, Yedid Elbez, Emmanuel Sorbets, Kim A Eagle, Deepak L Bhatt
BACKGROUND: The optimal blood pressure (BP) target to reduce the risk of cardiovascular (CV) events remains uncertain, especially in patients with coronary artery disease (CAD). Results from the Systolic Blood Pressure Intervention Trial (SPRINT) suggest that targeting a systolic BP<120mmHg decreases the rate of death and CV events in patients with hypertension and increased CV risk. We sought to evaluate the real-world applicability of SPRINT to patients with atherothrombosis. METHODS: We divided 35,411 hypertensive patients from the REACH registry into SPRINT-eligible and SPRINT-ineligible based on the trial's inclusion and exclusion criteria...
September 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28594053/therapeutic-strategies-for-atherosclerosis-and-atherothrombosis-past-present-and-future
#15
Christian Weber, Lina Badimon, François Mach, Emiel P C van der Vorst
Even two centuries after they were first described, atherosclerosis and atherothrombosis remain among the leading causes of death worldwide. Over the last decades it has become clear that atherosclerosis is not only a lipid-driven disease but also a multifactorial process largely driven by inflammatory mediators, an insight that has instigated additional research and drug development focussing on anti-inflammatory therapies. In this review, we will provide a brief historical overview, followed by a more general synopsis of the range of currently available state-of-the-art therapies for atherosclerosis and atherothrombosis...
June 28, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28584074/gut-derived-serum-lipopolysaccharide-is-associated-with-enhanced-risk-of-major-adverse-cardiovascular-events-in-atrial-fibrillation-effect-of-adherence-to-mediterranean-diet
#16
Daniele Pastori, Roberto Carnevale, Cristina Nocella, Marta Novo, Maria Santulli, Vittoria Cammisotto, Danilo Menichelli, Pasquale Pignatelli, Francesco Violi
BACKGROUND: Gut microbiota is emerging as a novel risk factor for atherothrombosis, but the predictive role of gut-derived lipopolysaccharide (LPS) is unknown. We analyzed (1) the association between LPS and major adverse cardiovascular events (MACE) in atrial fibrillation (AF) and (2) its relationship with adherence to a Mediterranean diet (Med-diet). METHODS AND RESULTS: This was a prospective single-center study including 912 AF patients treated with vitamin K antagonists (3716 patient-years)...
June 5, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28520215/aspirin-and-the-risk-of-cardiovascular-events-in-atherosclerosis-patients-with-and-without-prior-ischemic-events
#17
Anthony A Bavry, Islam Y Elgendy, Yedid Elbez, Ahmed N Mahmoud, Emmanuel Sorbets, Philippe Gabriel Steg, Deepak L Bhatt
BACKGROUND: The benefit of aspirin among patients with stable atherosclerosis without a prior ischemic event is not well defined. HYPOTHESIS: Aspirin would be of benefit in outpatients with atherosclerosis with prior ischemic events, but not in those without ischemic events. METHODS: Subjects from the Reduction of Atherothrombosis for Continued Health registry were divided according to prior ischemic event (n =21 724) vs stable atherosclerosis, but no prior ischemic event (n = 11 872)...
May 18, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28520087/geographic-variation-and-risk-factors-for-systemic-and-limb-ischemic-events-in-patients-with-symptomatic-peripheral-artery-disease-insights-from-the-reach-registry
#18
Jérémie Abtan, Deepak L Bhatt, Yedid Elbez, Emmanuel Sorbets, Kim Eagle, Christopher M Reid, Iris Baumgartner, David Wu, Mary E Hanson, Hakima Hannachi, Puneet K Singhal, Philippe Gabriel Steg, Gregory Ducrocq
BACKGROUND: Patients with symptomatic peripheral artery disease (PAD) are at high risk of ischemic events. However, data about predictors of this risk are limited. HYPOTHESIS: We analyzed baseline characteristics and 4-year follow-up of patients enrolled in the international REduction of Atherothrombosis for Continued Health (REACH) Registry with symptomatic PAD and no history of stroke/transient ischemic attack to describe annual rates of recurrent ischemic events globally and geographically...
May 18, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28507492/long-term-treatment-of-chronic-plaque-psoriasis-with-biological-drugs-can-control-platelet-activation-targeting-the-bridge-between-inflammation-and-atherothrombosis
#19
Bartłomiej Kwiek, Joanna Narbutt, Anna Sysa-Jędrzejowska, Andrzej Langner, Aleksandra Lesiak
INTRODUCTION: Platelet activation is elevated in moderate to severe psoriasis, and the reduction in platelet activation during short-term treatment has already been demonstrated. Soluble P-selectin is a well-established marker of platelet activation. AIM: To show whether the long-term treatment of psoriasis with biological drugs can reduce elevated platelet activation. MATERIAL AND METHODS: An observational study of 27 patients with chronic plaque psoriasis, treated with infliximab, adalimumab, etanercept, or ustekinumab for up to 12 months was conducted...
April 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28504650/neutrophil-derived-s100-calcium-binding-proteins-a8-a9-promote-reticulated-thrombocytosis-and-atherogenesis-in-diabetes
#20
Michael J Kraakman, Man Ks Lee, Annas Al-Sharea, Dragana Dragoljevic, Tessa J Barrett, Emilie Montenont, Debapriya Basu, Sarah Heywood, Helene L Kammoun, Michelle Flynn, Alexandra Whillas, Nordin Mj Hanssen, Mark A Febbraio, Erik Westein, Edward A Fisher, Jaye Chin-Dusting, Mark E Cooper, Jeffrey S Berger, Ira J Goldberg, Prabhakara R Nagareddy, Andrew J Murphy
Platelets play a critical role in atherogenesis and thrombosis-mediated myocardial ischemia, processes that are accelerated in diabetes. Whether hyperglycemia promotes platelet production and whether enhanced platelet production contributes to enhanced atherothrombosis remains unknown. Here we found that in response to hyperglycemia, neutrophil-derived S100 calcium-binding proteins A8/A9 (S100A8/A9) interact with the receptor for advanced glycation end products (RAGE) on hepatic Kupffer cells, resulting in increased production of IL-6, a pleiotropic cytokine that is implicated in inflammatory thrombocytosis...
June 1, 2017: Journal of Clinical Investigation
keyword
keyword
110759
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"